AXSM vs. TEVA, GMAB, ITCI, MRNA, SMMT, VTRS, RDY, SRPT, PCVX, and QGEN
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Summit Therapeutics (SMMT), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Axsome Therapeutics vs.
Teva Pharmaceutical Industries (NYSE:TEVA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.
In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Axsome Therapeutics. MarketBeat recorded 23 mentions for Teva Pharmaceutical Industries and 17 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.25 beat Teva Pharmaceutical Industries' score of 0.88 indicating that Axsome Therapeutics is being referred to more favorably in the news media.
Axsome Therapeutics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Teva Pharmaceutical Industries has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -74.47%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Axsome Therapeutics' return on equity.
54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Teva Pharmaceutical Industries has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
Teva Pharmaceutical Industries presently has a consensus price target of $23.43, indicating a potential upside of 43.25%. Axsome Therapeutics has a consensus price target of $167.36, indicating a potential upside of 33.67%. Given Teva Pharmaceutical Industries' higher probable upside, equities research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Axsome Therapeutics.
Teva Pharmaceutical Industries received 858 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 70.37% of users gave Axsome Therapeutics an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.
Summary
Teva Pharmaceutical Industries and Axsome Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AXSM) was last updated on 3/20/2025 by MarketBeat.com Staff
